AWM
KPTI icon

Activest Wealth Management’s Karyopharm Therapeutics KPTI Stock Holding History

Activest Wealth Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$645 Hold
66
– – ﹤0.01% 1022
2026
Q1 		$368 Hold
66
– – ﹤0.01% 1093
2025
Q4 		$486 Hold
66
– – ﹤0.01% 1001
2025
Q3 		$432 Hold
66
– – ﹤0.01% 975
2025
Q2 		$284 Hold
66
– – ﹤0.01% 939
2025
Q1 		$247 Sell
66
-1
-1% -$9 ﹤0.01% 922
2024
Q4 		$676 Hold
67
– – ﹤0.01% 499
2024
Q3 		$830 Hold
67
– – ﹤0.01% 468
2024
Q2 		$868 Buy
+67
New +$1.11K ﹤0.01% 443

Other funds holding KPTI

CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
SCM
Sterling Capital Management Charlotte, North Carolina $5.9B AUM 29.63% 1-Year Est. Return
MLA
MB, Levis & Associates Center Valley, Pennsylvania $271M AUM 15.56% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
WBC
West Branch Capital Amherst, Massachusetts $430M AUM 41.9% 1-Year Est. Return

Activest Wealth Management's KPTI Position: Q2 2026 in Review

Activest Wealth Management held its Karyopharm Therapeutics (KPTI) position steady in Q2 2026 at 66 shares worth $645. The position accounts for ﹤0.01% of the portfolio, ranked #1022.

Activest Wealth Management first reported a position in KPTI in Q2 2024 and has held it in 9 quarters since. The position peaked at $868 in Q2 2024. 9 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

  • Activest Wealth Management held 66 shares of Karyopharm Therapeutics worth $645 as of Q2 2026.
  • Activest Wealth Management left its Karyopharm Therapeutics share count unchanged in Q2 2026.
  • Karyopharm Therapeutics made up ﹤0.01% of Activest Wealth Management's portfolio in Q2 2026, its #1022 holding.
  • Activest Wealth Management first reported a position in Karyopharm Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • Activest Wealth Management's Karyopharm Therapeutics position peaked at $868 in Q2 2024.
  • 9 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on Activest Wealth Management's 13F filing for Q2 2026, filed 16 Jul 2026.